Revance Therapeutics

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revance Therapeutics excels in Q4 with DAXXIFY approval driving growth

Revance Therapeutics demonstrated strong financial performance and strategic focus in Q4 2022, driven by DAXXIFY sales and revenue growth.
The company's strengths lie in DAXXIFY approval, positive market feedback, and partnerships positioning them well for future growth.
Challenges include competitive dynamics, pricing strategies, and managing increased OpEx, while opportunities exist in market expansion and new product programs.
Overall, Revance is optimistic about their market position and future prospects, emphasizing customer relationships and strategic investments.

Revance Therapeutics posts stellar Q1 results, eyes market expansion

Revance Therapeutics delivered strong Q1 results, driven by robust RHA Collection and DAXXIFY sales, positioning the company for future growth.
While facing challenges in undisclosed market data and paused clinical trials, Revance's strategic focus on market entry and product adoption presents opportunities for expansion.
With a solid cash position, upcoming milestones, and market potential, Revance is poised for continued success in the neuromodulator and therapeutics segments.

Revance Therapeutics reports record revenue growth and strategic expansion

Revance Therapeutics had a robust Q2 2023, marked by strong revenue growth, expanded sales force, and successful marketing efforts.
While facing challenges in market reception and adoption rates for DAXXIFY, the company remains optimistic about driving growth and leveraging opportunities.
With a focus on sales force expansion, product education, and strategic initiatives, Revance is poised for continued commercial progress and success.

Revance Therapeutics reports strong Q3 growth driven by DAXXIFY

Revance Therapeutics is strategically focusing on DAXXIFY launch success, aesthetics growth, and therapeutics opportunities. Despite challenges in account responses and revenue guidance uncertainties, the company remains optimistic about expanding DAXXIFY adoption and maintaining a strong financial position.

Revance Therapeutics reports record revenue, eyes growth in 2024

Revance Therapeutics had a strong performance in 2023, focusing on growth and cost controls for future success.
The company's strategic initiatives and product offerings position it well for continued growth and market expansion.
Challenges in managing expenses and achieving profitability are being addressed with targeted strategies.
Optimism surrounds the potential of DAXXIFY and the company's ability to capitalize on market opportunities.

Revance Therapeutics (RVNC) reports strong Q1 performance and strategic market entry

Revance Therapeutics (RVNC) demonstrated strong performance in Q1 2024, driven by growth in DAXXIFY and RHA filler market share, with a strategic entry into the therapeutic neurotoxin market.
The company's focus on innovation, efficiency, and market expansion presents opportunities for revenue growth and competitive positioning, despite challenges in differentiation and market dynamics.
Efforts to drive product adoption, enhance customer engagement, and optimize operational efficiency underscore Revance's commitment to sustainable financial health and long-term success.
Overall, Revance's Q1 performance reflects positive momentum and strategic initiatives aimed at capitalizing on market opportunities and strengthening its competitive position.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Los Angeles, California--(Newsfile Corp. - October 25, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ: RVNC) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Revance is the subject of an FDA Form 483 posted on...

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Revance Therapeutics, Inc. and Encourages Investors with Losses To Contact the Firm

Boston, Massachusetts--(Newsfile Corp. - October 20, 2021) - The Thornton Law Firm alerts investors that it is investigating Revance Therapeutics, Inc. (NASDAQ: RVNC) for potential securities violations. Investors who currently own shares or options of RVNC may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Revance for more information. Investors may also email investors@tenlaw.com or call 617-531-3917. FOR MORE INFORMATION: www.tenlaw.com/cases/RevanceOn October 15, 2021, the U.S. Food and Drug Administration (FDA) issued a...

RVNC INVESTOR ALERT: Thornton Law Firm Announces Investigation

NEW YORK, Oct. 18, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC) resulting from allegations that Revance may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Revance securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

RVNC EQUITY ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors with Losses to Inquire About Class Action Investigation - RVNC

MILWAUKEE, Oct. 18, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Revance (NASDAQ: RVNC).  The investigation results from inaccurate statements Revance may have made regarding its business operations and prospects.

Ademi LLP Investigates Claims of Securities Fraud against Revance Therapeutics, Inc.

Revance Therapeutics Inc (NASDAQ:RVNC) is plummeting today, last seen down 41.9% to trade at $13.21.

Revance Therapeutics Stock Nosedives on FDA News

Shares in Revance Therapeutics dropped more than 40% Monday after the FDA rejected a license for the group's proposed treatment for frown lines.

Revance Stock Is Plunging. The FDA Won't Clear a Treatment for Frown Lines.

Valneva SE

The Nasdaq looks poised to open slightly lower after a strong week.

These 2 Nasdaq Biotechs Are Making Huge Premarket Moves Monday

Shares of Revance Therapeutics Inc. RVNC, +0.66% plummeted 34.7% toward an 18-month low in premarket Monday, which puts them on track for a record one-day selloff, after the company said the the Food and Drug Administration issued a Complete Response Letter (CRL) regarding the biotechnology company's treatment of glabellar, or frown, lines. The company said late Friday that FDA determined it could not approve the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection in its present form, citing deficiencies related to an inspection of Revance's manufacturing facility.

Revance Therapeutics plummets after FDA said it can't approve BLA of treatment for frown lines

Shares of Revance Therapeutics Inc. RVNC, +0.66% tumbled 35.3% in premarket trading on Monday after the company said Friday that the Food and Drug Administration had declined to approve Revance's application for a frown-line treatment. The FDA issued a complete response letter that the company received Oct. 15, citing issues with Revance's manufacturing facilities.

Revance's stock falls 35% after FDA says it won't approve the company's frown-line injection

A surprise rejection is weighing on the biopharma's shares today.

Why Revance Therapeutics Stock Is Getting Crushed Today

The FDA has issued a Complete Response Letter (CRL) regarding Revance Therapeutics Inc's (NASDAQ: RVNC) marketing application for DaxibotulinumtoxinA for Injection for moderate to severe glabellar (frown) lines. The agency indicated deficiencies related to the FDA's onsite inspection at Revance's manufacturing facility.

Revance Shares Plunge On FDA Response Letter For Frown Line Candidate

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Provides Regulatory Update on DaxibotulinumtoxinA for Injection for the Treatment of Moderate to Severe Glabellar (Frown) Lines

Revance Provides Regulatory Update on DaxibotulinumtoxinA for Injection for the Treatment of Moderate to Severe Glabellar (Frown) Lines

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC) resulting from allegations that Revance may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Revance securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arran

RVNC BREAKING NEWS: ROSEN, A TOP RANKED LAW FIRM, Encourages Revance Therapeutics, Inc. Investors with Losses to Inquire About Class Action Investigation – RVNC

The stock price of Revance Therapeutics Inc (NASDAQ: RVNC) increased by over 12% today. This is why it happened.

RVNC Stock: Why It Substantially Increased Today

New York, New York--(Newsfile Corp. - October 13, 2021) -  Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) concerning possible violations of federal securities laws.On October 12, 2021, Revance revealed the U.S. Food and Drug Administration ("FDA") posted Form 483 to its website citing issues found during the inspection of a Revance Therapeutics, Inc. facility in July 2021. Among other def

EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Revance Therapeutics, Inc.

Management's response to a publicly disclosed regulatory form has investors doing a U-turn.

Why Revance Therapeutics Stock Is Bolting Higher Today

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Continues to Anticipate FDA Approval of DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines in 2021

Revance Continues to Anticipate FDA Approval of DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines in 2021

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces the Launch of OPUL™, the First-of-its-Kind Relational Commerce Platform for Aesthetic Practices

Revance Announces the Launch of OPUL™, the First-of-its-Kind Relational Commerce Platform for Aesthetic Practices

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Showcase Data from Phase 3 ASPEN-1 Clinical Trial at International Parkinson and Movement Disorder Society Virtual Congress 2021

Revance to Showcase Data from Phase 3 ASPEN-1 Clinical Trial Evaluating Efficacy, Duration of Effect and Safety of DaxibotulinumtoxinA for Injection for Cervical Dystonia at International Parkinson and Movement Disorder Society Virtual Congress 2021

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Presents Data on the RHA® Collection of Dermal Fillers at the 2021 Virtual Skin of Color Update Meeting

Revance Presents Data on the RHA® Collection of Dermal Fillers at the 2021 Virtual Skin of Color Update Meeting

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Participate in the Wells Fargo Securities Healthcare Conference

Revance to Participate in the Wells Fargo Securities Healthcare Conference

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Publishes SAKURA Results on Static Glabellar Lines with Repeated Treatment of DaxibotulinumtoxinA for Injection in Dermatologic Surgery

Revance Announces Publication of Results on Static Glabellar Lines With Repeated Treatment of DaxibotulinumtoxinA for Injection From the SAKURA Clinical Program in Dermatologic Surgery

Despite the recent selloff, shares of Revance Therapeutics are up 65% since I gave a very bullish recommendation 2 years ago. In that time, we have have seen an equity raise, acquisition of sales rights for RHA fillers from Teoxane, a convertible note offering and of course the COVID-19 pandemic.

Revance Therapeutics: Frowning At The FDA

Revance Therapeutics, Inc. (RVNC) CEO Mark Foley on Q2 2021 Results - Earnings Call Transcript

NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Second Quarter 2021 Financial Results, Provides Corporate Update

News for Revance Therapeutics Stock (RVNC)